Feature | June 09, 2014

ORBIT II Study One-Year Results Demonstrate Orbital Atherectomy Improves Outcomes in High-Risk Patients

Sanding away calcium in coronary arteries improves stent deployment, long-term outcomes

June 9, 2014 — After one year, patients treated with orbital atherectomy, a procedure to sand away calcium in the coronary arteries prior to stenting, were less likely to require a repeat procedure to reopen their vessel or suffer a heart attack or death compared to other published trials in patients with heavily calcified arteries. The new results from the ORBIT II study were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 scientific sessions in Las Vegas.

The ORBIT II study is the first to exclusively investigate severely calcified lesions, and it studied high-risk patients that are usually excluded from large clinical trials, including those on dialysis or with low left ventricular ejection fraction (>25 percent). In patients treated with percutaneous coronary intervention (PCI), calcified lesions are associated with greater frequency of stent under expansion, which may result in the need for repeat coronary intervention and coronary artery bypass graft surgery (CABG).

“Often patients with calcified lesions are more difficult to treat because the calcium can interfere with proper stent placement,” said Jeffrey Chambers, M.D., FSCAI, director of the cardiac catheterization laboratory, Mercy Hospital, Minneapolis, and the study’s principal investigator. “If the stent cannot be placed properly the patient may need additional procedures and even surgery.”

In the trial, investigators treated patients using the Diamondback 360 orbital atherectomy system (OAS). The catheter-based device’s crown rotates in the artery to sand the calcified portion of the plaque into minuscule particles. The device received U.S. Food and Drug Administration (FDA) approval in October 2013.

The study, involving 443 patients at 49 U.S. sites, demonstrated that OAS aids stent delivery, with promising one-year outcomes: 94.1 percent of patients were free from target vessel revascularization (TVR) and target lesion revascularization (TLR). Investigators also reported lower rates of cardiac death (97 percent freedom from cardiac death).

The study also reviews cost differences between patients who received OAS prior to stenting and those who did not. Using a sample of patients derived from 2012 Medicare data, they compared typical treatment costs to ORBIT II patients who were pre-treated with OAS. Mean costs were $3,198 lower (p=0.003) in ORBIT II patients compared to Medicare patients.

“In addition to patient clinical outcomes, pre-treatment of these difficult-to-treat, severely calcified lesions with coronary OAS resulted in cost savings due to more efficient procedures and lower readmission rates,” said Chambers. “In an era where we are treating more patients while aiming to achieve better outcomes at greater value, these findings are significant. Not only does this procedure improve care, but it can do so more efficiently.”

Chambers receives consulting fees/honoraria from Cardiovascular Systems Inc., manufacturer of the Diamondback system.

For more information: www.scai.org

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo